Archives
-
Cisplatin (CDDP): Mechanism and Research Workflow
2026-09-17
Cisplatin, also called CDDP, is a platinum-based DNA crosslinking agent that forms guanine adducts and can trigger apoptosis. This article connects its molecular mechanism with cancer research applications, SCLC clinical context, formulation limits, xenograft studies, and chemotherapy resistance workflows.
-
In Vitro Drug Response Metrics in Cancer
2026-09-16
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing why growth inhibition and cell death should not be treated as interchangeable drug-response outcomes. The framework offers a practical basis for designing time-resolved cancer assays and interpreting PARP-focused experiments more accurately.
-
Mitoxantrone HCl: Workflow for DNA Damage Studies
2026-09-16
Mitoxantrone HCl supports reproducible studies of topoisomerase II–linked DNA damage, apoptosis, cell-cycle disruption, and immune-cell modulation. A practical workflow also enables investigators to test its emerging allosteric effects on ERα, including activity against endocrine-resistant receptor mutants.
-
E-64d Workflows for Intracellular Calpain Studies
2026-09-15
E-64d provides a practical way to inhibit intracellular calpain and related cysteine proteases in intact cells, with applications spanning platelet activation, apoptosis, neuroprotection, and cancer research. This guide connects dose planning, autophagy-aware interpretation, and troubleshooting to more reproducible experiments.
-
GSK-923295 for CENP-E Mitotic Assays
2026-09-15
GSK-923295 is a potent CENP-E inhibitor for resolving chromosome congression, mitotic arrest, and centromere defects in cell-based cancer research. This guide connects compound handling with quantitative imaging, CTCF-depletion comparisons, cell-growth assays, and translational interpretation in colon cancer xenograft models.
-
Cucurbitacin I: From STAT3 Biology to Translation
2026-09-14
A mechanism-led guide to using Cucurbitacin I (JSI-124) to connect STAT3 target engagement with cancer phenotypes, multicellular model logic, and translational decision-making.
-
Estradiol, ER Signaling, and CD4+ T Cells After Shock
2026-09-14
This 2021 Scientific Reports study shows that estradiol restores splenic CD4+ T-cell proliferation and cytokine production after hemorrhagic shock by reducing endoplasmic reticulum stress. Pharmacological comparisons identify ERα and GPR30, but not ERβ, as key components of this protective response.
-
Gramine–CUL3–MTDH Ferroptosis in TNBC
2026-09-13
The reference study identifies Gramine as a candidate ferroptosis inducer that suppresses triple-negative breast cancer through a CUL3–MTDH regulatory axis. By combining target-engagement assays, genetic perturbation, ferroptosis rescue, and mouse models, the work connects Gramine activity to altered MTDH stability and weakened SLC3A2–GPX4 antioxidant defense.
-
Gemcitabine HCl for MRI-Guided PDAC Studies
2026-09-12
Gemcitabine HCl connects mechanism-based cytotoxicity with longitudinal MRI, allowing researchers to compare cell-level sensitivity with whole-tumor response in pancreatic cancer models. This workflow combines formulation control, in vitro cytotoxicity testing, and multianimal imaging for more efficient preclinical treatment studies.
-
BMS-345541: IKK-1/IKK-2 Inhibitor Workflows
2026-09-11
Build cleaner NF-κB experiments with BMS-345541, from cytokine profiling in THP-1 cells to pathway dissection in angiogenesis and cancer models. This workflow-focused guide covers dose selection, orthogonal readouts, formulation, and troubleshooting for inflammation research and apoptosis studies.
-
Dihydroethidium (DHE) for Live-Cell Superoxide Assays
2026-09-11
Build a practical Dihydroethidium workflow for relative superoxide monitoring in live cells, with assay choices tailored to mitochondrial injury models. This guide connects DHE imaging to the irisin–renal ischemia–reperfusion study and emphasizes controls, normalization, and troubleshooting rather than fluorescence alone.
-
WEHI-539: Mapping BCL-XL-Dependent Apoptosis
2026-09-10
WEHI-539 is a selective BCL-XL inhibitor for dissecting mitochondrial apoptosis, resistance, and cancer stem cell survival. This article presents an assay-centered framework that connects BCL-XL dependency with MCL-1 compensation and experimental design.
-
PDHA1 Succinylation in Cholangiocarcinoma Therapy
2026-09-10
The reference study identifies PDHA1 K83 succinylation as a metabolic–immune link in cholangiocarcinoma, connecting altered tricarboxylic acid cycle activity and α-ketoglutaric acid accumulation with impaired macrophage antigen presentation. Its findings suggest that inhibiting this pathway with CPI-613 can improve the response to gemcitabine plus cisplatin, although validation across patient-derived models and clinical studies remains necessary.
-
High-Throughput BBB Model with Lysosomal Correction
2026-09-09
Hu and colleagues developed a Transwell surrogate blood-brain barrier model using LLC-PK1-MOCK/MDR1 cells to combine passive permeability assessment with P-glycoprotein efflux measurement. By correcting lysosomal trapping with Bafilomycin A1, the platform improved interpretation of low-recovery compounds and showed useful agreement between in vitro permeability and in vivo unbound brain distribution.
-
5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine
2026-09-09
Build reproducible α2-adrenergic receptor signaling experiments with a DMSO-soluble agonist suited to receptor pharmacology, immune microenvironment studies, and post-surgical osteosarcoma recurrence models. The workflow emphasizes vehicle controls, hydrogel formulation, immune-competent comparisons, and troubleshooting of precipitation, cytotoxicity, and stability.